Johnson Mary A

Johnson Mary A, Mehrabian Zara, Guo Yan, Ghosh Joy, Brigell Mitchell G, Bernstein Steven L

An anti-NOGO antibody in rats with NAION preserved optic nerve function and reduced inflammation. This suggests a potential neuroprotective treatment for this currently untreatable condition.

Johnson Mary A, Miller Neil R, Nolan Theresa, Bernstein Steven L

In a primate NAION model, initial optic nerve swelling strongly predicted the severity of subsequent nerve atrophy, indicating swelling magnitude forecasts future damage.

Miller Neil R, Johnson Mary A, Nolan Theresa, Guo Yan, Bernstein Steven L

This primate study found a single ranibizumab injection immediately after NAION onset offered no neuroprotection, suggesting it's ineffective for preserving vision in this condition.

Touitou Valerie, Johnson Mary A, Guo Yan, Miller Neil R, Bernstein Steven L

A single intravitreal PGJ2 injection was safe and neuroprotective in a rodent AION model, preserving RGCs and vision. This offers a potential treatment for NAION.

Bernstein Steven L, Johnson Mary A, Miller Neil R

New NAION models reveal early inflammation and ganglion cell loss. Modulating this inflammation early may offer a crucial treatment strategy for this untreatable condition.

Chen Celia S, Johnson Mary A, Flower Robert A, Slater Bernard J, Miller Neil R, Bernstein Steven L

This primate NAION model, induced by photoembolism, closely mimics human NAION's optic disc edema, atrophy, and inflammation. It's a valuable tool for testing new neuroprotective treatments.

Bernstein Steven L, Guo Yan, Kelman Shalom E, Flower Robert W, Johnson Mary A

This study developed a rodent AION model, finding rapid functional and cellular changes mimicking human AION. This model offers a platform for detailed disease analysis and therapeutic development.